Lymphoma Cancer | Tumor

FDA Approves Zynlonta for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

April 23rd 2021, 7:16pm

Article

The FDA has approved Zynlonta (loncastuximab tesirine-lpyl) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Friday Frontline: A 22-Year-Old Cancer Survivor Prepares to Bike Across the Country, Actress Helen McCrory Dies From Cancer, And More

April 23rd 2021, 3:00pm

Article

From a college student who survived lymphoma biking 4,000 miles for charity to the death of “Harry Potter” actress Helen McCrory, here’s what’s happening in the cancer landscape this week.

Keytruda Improves Progression-Free Survival in Subset of Patients With Relapsed/Refractory Hodgkin Lymphoma

April 19th 2021, 9:00pm

Article

Median progression-free survival in patients treated with Keytruda was 13.2 months versus 8.3 months with Adcetris, which makes Keytruda an “effective treatment option” for patients in this population who were either ineligible for or relapsed after autologous hematopoietic stem cell transplantation.

How TikTok Helped One Survivor Discover Connection and Community

April 15th 2021, 9:00pm

Article

Lymphoma survivor Nina Luker talks about receiving a diagnosis at age 24 and how sharing her story with nearly 200,000 supporters on social media helped her find purpose.

Investigational Drug Shows Promise in Lymphoma Subsets

April 6th 2021, 3:00pm

Article

Early findings show that glofitamab may be a safe and effective option for patients with pretreated, relapsed/refractory B-cell non-Hodgkin lymphoma.

How a Handmade Care Package Inspired One Cancer ‘Alumni’ to Create ‘Kits to Heart’

March 25th 2021, 3:00pm

Podcast

In this episode of the “CURE® Talks Cancer” podcast, we spoke with a large B-cell lymphoma “alumni” who was diagnosed at 24 about what it was like to be the only young patient receiving infusions at her cancer center, and what led her to start a nonprofit organization to help others along their journey.

R-CHOP Plus Revlimid Shows Tolerable Safety Profile, But Does Not Improve Progression-Free Survival

March 22nd 2021, 9:00pm

Article

For patients with B-cell lymphoma, the addition of Revlimid to standard R-CHOP did not improve progression-free survival nor event-free survival.

How TikTok Helped One Cancer Survivor Find Connection and Community

March 11th 2021, 4:00pm

Podcast

This week on the “CURE® Talks Cancer” podcast, we spoke with lymphoma survivor Nina Luker about what it was like to receive a diagnosis at age 24, and how sharing her story with nearly 200,000 supporters on TikTok and Instagram led her to find purpose with the Lymphoma Research Foundation.

Cancer Survivor Offers Tips on How to Help Loved Ones Get Through Difficult Times

March 9th 2021, 7:00pm

Video

Nearly one year ago to the day, 24-year-old Nina Luker was completely blindsided by a diagnosis of non-Hodgkin lymphoma. But after powering through treatments in the thick of the COVID-19 pandemic, Luker is now cancer-free and offering advice to those who may be looking for ways to help their loved ones through difficult times of their own.

5 Recent Cancer Drug Approvals Patients May Have Missed

February 26th 2021, 7:00pm

Article

Throughout the winter, the FDA has continued to approve several new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.